Pharma-Bio Serv (PBSV) Price to Earnings (2010 - 2026)

Pharma-Bio Serv (PBSV) has reported Price to Earnings for 17 consecutive years, with 49.15 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Earnings fell 55.57% year-over-year to 49.15; the trailing twelve-month figure through Apr 2026 stood at 220.48 (up 495.49% YoY), and the FY2025 full-year result was 123.12, down 619.02% from the prior year.
• Price to Earnings fell to 49.15 in Q2 2026 per PBSV's latest filing, from 411.22 in the prior quarter.
• Across five years, Price to Earnings topped out at 1613.74 in Q1 2025 and bottomed at 121267.02 in Q4 2025.
• Historically, Price to Earnings has averaged 6580.38 across 5 years, with a median of 56.94 in 2023.
• The sharpest annual moves came in 2022 and 2025: Price to Earnings jumped 2440.42% in 2022, then tumbled 14772.38% in 2025.
• Over 5 years, Price to Earnings stood at 113.81 in 2022, then plunged by 463.77% to 413.99 in 2023, then surged by 299.64% to 826.5 in 2024, then sank by 14772.38% to 121267.02 in 2025, then soared by 100.04% to 49.15 in 2026.
• According to Business Quant data, Price to Earnings over the past three periods registered 49.15, 411.22, and 121267.02 for Q2 2026, Q1 2026, and Q4 2025 respectively.